Levetiracetam (LEV) is one of second-generation antiepileptic drugs that has been used to treat partial and generalized epilepsy. LEV is eliminated from the systemic circulation by renal excretion. Therefore, patients with renal impairment may experience a reduced drug excretion and increased adverse drug reactions. Moreover, patients with end-stage renal disease who need dialysis may experience low serum LEV concentration because of drug loss via dialysis. LEV loss via dialysis can cause low serum level of LEV that insufficient for seizure control. The present study was aimed to evaluate pharmacokinetics of LEV in patients undergoing 4 hour-intermittent hemodialysis (IHD). The results of the study may benefit to determine the appropriate LEV initial dose and supplemental dose for patients undergoing IHD.
Study Type
OBSERVATIONAL
Enrollment
12
Pharmongkutklao Hospital
Ratchathewi, Bangkok, Thailand
Plasma concentration of Levetiracetam
Measured Levetiracetam plasma concentration (mcg/mL) of the subjects on dialysis day
Time frame: Immediately before an initiation of an intermittent hemodialysis session
Plasma concentration of Levetiracetam
Measured Levetiracetam plasma concentration (mcg/mL) of the subjects on dialysis day
Time frame: 1 hour after an initiation of an intermittent hemodialysis session
Plasma concentration of Levetiracetam
Measured Levetiracetam plasma concentration (mcg/mL) of the subjects on dialysis day
Time frame: 2 hour after an initiation of an intermittent hemodialysis session
Plasma concentration of Levetiracetam
Measured Levetiracetam plasma concentration (mcg/mL) of the subjects on dialysis day
Time frame: 3 hour after an initiation of an intermittent hemodialysis session
Plasma concentration of Levetiracetam
Measured Levetiracetam plasma concentration (mcg/mL) of the subjects on dialysis day
Time frame: 4 hour after an initiation of an intermittent hemodialysis session
Plasma concentration of Levetiracetam
Measured Levetiracetam plasma concentration (mcg/mL) of the subjects on dialysis day
Time frame: Before an administration of Levetiracetam post-hemodialysis supplemental dose
Plasma concentration of Levetiracetam
Measured Levetiracetam plasma concentration (mcg/mL) of the subjects on dialysis day
Time frame: 1 hour after finishing an administration of Levetiracetam post-hemodialysis supplemental dose
Plasma concentration of Levetiracetam
Measured Levetiracetam plasma concentration (mcg/mL) of the subjects on non-dialysis day.
Time frame: Immediately before Levetiracetam administration
Plasma concentration of Levetiracetam
Measured Levetiracetam plasma concentration (mcg/mL) of the subjects on non-dialysis day.
Time frame: 1 hour after finishing Levetiracetam administration
Number of participants with adverse drug reactions from Levetiracetam
Observed signs and symptoms of Levetiracetam adverse drug reactions after participants were administered with Levetiracetam.
Time frame: From the first day that participants were included to the study and treated with Levetiracetam until the date of the last point of serum Levetiracetam sampling, assessed up to 3 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.